Skip to content

BioNTech SE Sustainability Reports

BioNTech SE is a biotechnology company that develops next-generation immunotherapies and vaccines for cancer and infectious diseases. The company pioneers mRNA-based therapies, next-generation immunomodulators, and antibody-drug conjugates to leverage the human immune system.

Sector: Professional & technical services

Country: Germany

Exchange: Deutsche Börse (Xetra)

ISIN: US09075V1026

16 reports from 2019 to 2025